A startup co‑founded by gene‑editing experts including Fyodor Urnov, with advisory support from Jennifer Doudna, launched Aurora Therapeutics after a $16 million seed from Menlo Ventures. The company aims to scale bespoke CRISPR‑based therapies that correct ultra‑rare mutations by grouping variants under regulatory pathways the FDA has signaled are feasible. Aurora’s initial program targets phenylketonuria (PKU) and will pursue a regulatory strategy that leverages the FDA’s plausible‑mechanism pathway for personalized therapies. The seed funding and regulatory framing reflect growing investor and agency openness to ‘bespoke’ genetic medicines.